FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2772080214> ?p ?o ?g. }

• W2772080214 endingPage "1637" @default.
• W2772080214 startingPage "1637" @default.
• W2772080214 abstract "Background: Patients with myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), experience a high symptom burden that compromises daily functioning and quality of life. Objective: To describe the prevalence and nature of medical disability leave (MDL) among patients with MPNs, and its relationship with MPN symptoms. Methods: An online survey of adult patients (aged 18-70 years) with MF, PV, or ET in the United States was conducted between April and November of 2016. Data collected included patient demographics, MPN diagnosis, MDL due to MPNs since diagnosis (short-term or long-term, date of leave and return), history of thrombotic events, MPN-related symptoms (using the MPN Symptom Assessment Form [MPN-SAF]), and physical, mental, and social functional status in the prior 7 days. MPN total symptom score (TSS) was calculated as the sum of the scores for the 10 symptoms included in the MPN-SAF. Symptoms and functional status were compared between patients who took MDL and patients with no employment change using the t-test and chi-square test, respectively. Results: Among the total of 904 patients that participated in the survey, 592 patients were employed at the time of MPN diagnosis; 147 (24.8%) subsequently took MDL because of their MPN (MF, 66/174 [37.9%]; PV, 55/248 [22.2%]; ET, 26/170 [15.3%]; Table 1 ), 293 (49.5%) reported no change in employment because of their MPN, and the remaining152 patients had other employment change (e.g., early retirement, hour reduction). Among patients who took MDL, the mean age at diagnosis was 46 years, 66% were female, the mean duration of disease was 6.6 years, and 31% had a history of thrombotic event (TE). Among patients with no employment change, the mean age at diagnosis was 48 years, 71% were female, the mean duration of disease was 5.9 years, and 15.4% had a history of TEs. The mean time from MPN diagnosis to the first MDL was 2.3 years. Overall, 29.9% of patients took ≥2 MDLs, 48.3% took long-term leave, and by the time of the survey 62.6% did not return to work after their latest MDL. Among those who returned to work, the mean length of leave was 4.3 months; 46.3% of those who took MDL received social security benefits. A significantly higher symptom burden was reported among those who had gone on MDL compared with those with no employment change (mean MPN-TSS: 42.9 vs 20.1; P Table 2 ). Fatigue or tiredness, bone pain, and day or night sweats were the most severe symptoms among patients who took MDL. A higher proportion of patients who took MDL vs patients with no employment change had functional impairments, such as difficulty with strenuous physical activities (91.2% vs 64.8%), remembering things (90.5% vs 60.8%), and sleeping (84.4% vs 58.7%; all P Conclusions: Approximately one quarter of employed patients took MDL because of their MPN, nearly one half of whom took long-term leave. Patients who took MDL had significantly higher symptom burden vs those with no employment change. Most patients who went on MDL did not return to the workforce. Effectively managing MPN diseases and associated symptoms may reduce disability leave among those patients. Disclosures Yu: Incyte Corporation: Employment, Equity Ownership. Paranagama: Incyte Corporation: Employment, Equity Ownership. Parasuraman: Incyte Corporation: Employment, Equity Ownership. Mesa: Galena: Consultancy; Gilead: Research Funding; Incyte Corporation: Research Funding; Novartis: Consultancy; Ariad: Consultancy; Celgene: Research Funding; Promedior: Research Funding; CTI: Research Funding." @default.
• W2772080214 created "2017-12-22" @default.
• W2772080214 creator A5039013983 @default.
• W2772080214 creator A5039057642 @default.
• W2772080214 creator A5060196258 @default.
• W2772080214 creator A5087187822 @default.
• W2772080214 creator A5091492816 @default.
• W2772080214 date "2017-12-07" @default.
• W2772080214 modified "2023-09-28" @default.
• W2772080214 title "Role of Symptom Burden in Disability Leave Among Patients with Myeloproliferative Neoplasms (MPNs): Findings from the Living with MPN Patient Survey" @default.
• W2772080214 doi "https://doi.org/10.1182/blood.v130.suppl_1.1637.1637" @default.
• W2772080214 hasPublicationYear "2017" @default.
• W2772080214 type Work @default.
• W2772080214 sameAs 2772080214 @default.
• W2772080214 citedByCount "0" @default.
• W2772080214 crossrefType "journal-article" @default.
• W2772080214 hasAuthorship W2772080214A5039013983 @default.
• W2772080214 hasAuthorship W2772080214A5039057642 @default.
• W2772080214 hasAuthorship W2772080214A5060196258 @default.
• W2772080214 hasAuthorship W2772080214A5087187822 @default.
• W2772080214 hasAuthorship W2772080214A5091492816 @default.
• W2772080214 hasConcept C126322002 @default.
• W2772080214 hasConcept C144024400 @default.
• W2772080214 hasConcept C149923435 @default.
• W2772080214 hasConcept C159110408 @default.
• W2772080214 hasConcept C1862650 @default.
• W2772080214 hasConcept C2778837598 @default.
• W2772080214 hasConcept C2779951463 @default.
• W2772080214 hasConcept C2780007613 @default.
• W2772080214 hasConcept C2780076729 @default.
• W2772080214 hasConcept C2780084366 @default.
• W2772080214 hasConcept C2781057849 @default.
• W2772080214 hasConcept C71924100 @default.
• W2772080214 hasConceptScore W2772080214C126322002 @default.
• W2772080214 hasConceptScore W2772080214C144024400 @default.
• W2772080214 hasConceptScore W2772080214C149923435 @default.
• W2772080214 hasConceptScore W2772080214C159110408 @default.
• W2772080214 hasConceptScore W2772080214C1862650 @default.
• W2772080214 hasConceptScore W2772080214C2778837598 @default.
• W2772080214 hasConceptScore W2772080214C2779951463 @default.
• W2772080214 hasConceptScore W2772080214C2780007613 @default.
• W2772080214 hasConceptScore W2772080214C2780076729 @default.
• W2772080214 hasConceptScore W2772080214C2780084366 @default.
• W2772080214 hasConceptScore W2772080214C2781057849 @default.
• W2772080214 hasConceptScore W2772080214C71924100 @default.
• W2772080214 hasLocation W27720802141 @default.
• W2772080214 hasOpenAccess W2772080214 @default.
• W2772080214 hasPrimaryLocation W27720802141 @default.
• W2772080214 hasRelatedWork W2020316791 @default.
• W2772080214 hasRelatedWork W2065320932 @default.
• W2772080214 hasRelatedWork W2412769467 @default.
• W2772080214 hasRelatedWork W2418564351 @default.
• W2772080214 hasRelatedWork W2418827576 @default.
• W2772080214 hasRelatedWork W2531766651 @default.
• W2772080214 hasRelatedWork W2562042662 @default.
• W2772080214 hasRelatedWork W2585907801 @default.
• W2772080214 hasRelatedWork W2588249990 @default.
• W2772080214 hasRelatedWork W2588634825 @default.
• W2772080214 hasRelatedWork W2593644059 @default.
• W2772080214 hasRelatedWork W2756367435 @default.
• W2772080214 hasRelatedWork W2768676673 @default.
• W2772080214 hasRelatedWork W2794821874 @default.
• W2772080214 hasRelatedWork W2909029846 @default.
• W2772080214 hasRelatedWork W3024666062 @default.
• W2772080214 hasRelatedWork W3097041936 @default.
• W2772080214 hasRelatedWork W3124337447 @default.
• W2772080214 hasRelatedWork W3169915200 @default.
• W2772080214 hasRelatedWork W627123295 @default.
• W2772080214 hasVolume "130" @default.
• W2772080214 isParatext "false" @default.
• W2772080214 isRetracted "false" @default.
• W2772080214 magId "2772080214" @default.
• W2772080214 workType "article" @default.